EGFR and cancer: C225 acts as a signaling inhibitor via binding to the accessible extracellular domain of EGFR for blocking EGFR activity and inhibiting the unregulated progression of cell cycle [38], and has been approved by the FDA (Food and Drug Administration) for the treatment of a variety of EGFR-positive cancers [39].